- Home
- REE vs BCTX Comparison
REE vs BCTX Comparison
Compare REE & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- BCTX
- Stock Information
- Founded
- REE 2011
- BCTX 2014
- Country
- REE Israel
- BCTX Canada
- Employees
- REE N/A
- BCTX N/A
- Industry
- REE Auto Manufacturing
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- BCTX Health Care
- Exchange
- REE Nasdaq
- BCTX Nasdaq
- Market Cap
- REE 22.4M
- BCTX 19.0M
- IPO Year
- REE N/A
- BCTX N/A
- Fundamental
- Price
- REE N/A
- BCTX N/A
- Analyst Decision
- REE Strong Buy
- BCTX Strong Buy
- Analyst Count
- REE 2
- BCTX 1
- Target Price
- REE $11.75
- BCTX $40.00
- AVG Volume (30 Days)
- REE 135.6K
- BCTX 77.8K
- Earning Date
- REE 09-16-2025
- BCTX 10-28-2025
- Dividend Yield
- REE N/A
- BCTX N/A
- EPS Growth
- REE N/A
- BCTX N/A
- EPS
- REE N/A
- BCTX N/A
- Revenue
- REE $183,000.00
- BCTX N/A
- Revenue This Year
- REE $6,661.20
- BCTX N/A
- Revenue Next Year
- REE $2,240.01
- BCTX N/A
- P/E Ratio
- REE N/A
- BCTX N/A
- Revenue Growth
- REE N/A
- BCTX N/A
- 52 Week Low
- REE $0.53
- BCTX $6.00
- 52 Week High
- REE $11.72
- BCTX $190.50
- Technical
- Relative Strength Index (RSI)
- REE 57.71
- BCTX 84.38
- Support Level
- REE $0.68
- BCTX $12.50
- Resistance Level
- REE $0.84
- BCTX $13.60
- Average True Range (ATR)
- REE 0.07
- BCTX 0.67
- MACD
- REE 0.00
- BCTX 0.06
- Stochastic Oscillator
- REE 57.00
- BCTX 84.88
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.